Compare FOIL & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Londian Wason New Energy Tech Inc. American Depositary Shares each representing five Ordinary Shares
Current Price
Current Price
| Metric | FOIL | CORT |
|---|---|---|
| Founded | N/A | 1998 |
| Country | | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.6B | 9.7B |
| IPO Year | 2024 | 2001 |
| Metric | FOIL | CORT |
|---|---|---|
| Price | $18.93 | $117.02 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $96.50 |
| AVG Volume (30 Days) | 26.9K | ★ 843.5K |
| Earning Date | N/A | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.09 |
| Revenue | N/A | ★ $761,407,000.00 |
| Revenue This Year | N/A | $26.08 |
| Revenue Next Year | N/A | $26.98 |
| P/E Ratio | ★ N/A | $1,264.00 |
| Revenue Growth | N/A | ★ 12.79 |
| 52 Week Low | $19.00 | $28.66 |
| 52 Week High | $25.44 | $126.38 |
| Indicator | FOIL | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 26.41 | 51.60 |
| Support Level | $19.50 | $108.25 |
| Resistance Level | $23.27 | $124.30 |
| Average True Range (ATR) | 1.32 | 5.07 |
| MACD | -0.16 | -0.65 |
| Stochastic Oscillator | 17.67 | 52.64 |
Londian Wason New Energy Tech Inc is engaged in the research, development, and manufacture of electrolytic copper foil. Its product portfolio includes lithium-ion battery (LiB) copper foil, printed circuit board (PCB)-grade copper foil, and flexible copper clad laminates (FCCLs). Its products are used in applications including electric vehicles, energy storage systems, communication equipment, and consumer electronics. The company derives its revenue from contracts with customers, including the sales of LiB copper foil, PCB-grade copper foil and others in the PRC.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.